◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY

HomeAll stocks › FATE

Fate Therapeutics, Inc. (FATE) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-07-09

Fate Therapeutics, Inc. (FATE) operates in the Biotechnology industry and is headquartered in San Diego, United States with about 161 employees. Its market capitalization is roughly $360 million. In the fiscal year ended 2025-12-31, FATE reported $7M in revenue and ($136M) in net income.

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally.

Interactive charts & full statements → Open the FATE valuation workbench →

FATE Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Revenue$7M$14M$64M$96M
Operating Income (EBIT)($148M)($196M)($190M)($308M)
Net Income($136M)($186M)($161M)($282M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

FATE Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement2026-03-312025-12-312025-09-302025-06-302025-03-31
Total Revenue$1M$1M$2M$2M$2M
Operating Income (EBIT)($33M)($35M)($35M)($37M)($41M)
Net Income($31M)($32M)($32M)($34M)($38M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

FATE Free Cash Flow History

FATE Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Assets$319M$441M$506M$706M
Total Liabilities$112M$122M$138M$222M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive FATE viewer.

Other Companies in Biotechnology

← FASTAll stocksFATN →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.